Cytokinetics
CYTK
122 hedge funds and large institutions have $380M invested in Cytokinetics in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 17 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
22% more capital invested
Capital invested by funds: $311M → $380M (+$69.1M)
1.52% more ownership
Funds ownership: 69.19% → 70.71% (+1.5%)
5% more call options, than puts
Call options by funds: $917K | Put options by funds: $875K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 126 → 122 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.05M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$2.84M |
| 4 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$1.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.92M |
| 2 |
Millennium Management
New York
|
-$1.87M |
| 3 |
Goldman Sachs
New York
|
-$1.13M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$952K |
| 5 |
PA
Pinnacle Associates
New York
|
-$875K |
CYTK Hedge Fund Activity: Q3 2018 in Review
122 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2018, worth a combined $380M — up 22% from $311M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CYTK and 14 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 46 added.
The largest buyer was BlackRock, adding an estimated $6.05M. The largest seller was BVF Inc, cutting an estimated $2.92M.
- 122 institutional investors held Cytokinetics (CYTK) as of Q3 2018, down from 126 in Q2 2018.
- Funds reported $380M of Cytokinetics stock for Q3 2018, up 22% quarter-over-quarter.
- 14 funds opened new Cytokinetics positions in Q3 2018 and 17 closed out, a net change of -3 holders.
- The largest Cytokinetics buyer in Q3 2018 was BlackRock, an estimated $6.05M added.
- The largest Cytokinetics seller in Q3 2018 was BVF Inc, an estimated $2.92M sold.
Based on aggregated 13F filings for Q3 2018.